Paul M. Bisaro
Independent Director
Former Executive Chairman, Amneal Pharmaceuticals, Inc.
Director since
May 2015
Committees
Corporate Governance; Quality and Innovation
Other Current Public Company Directorships
Myriad Genetics, Inc. (since October 2022)
Keenova Therapeutics plc (formerly Mallinckrodt plc) (since July 2025 and previously from 2022-June 2025)
Mr. Bisaro provides exceptional global healthcare and pharmaceutical industry expertise from his prior senior executive leadership roles, including as President and CEO of Actavis and Executive Chairman of Allergan, with deep knowledge of manufacturing processes, R&D, product liability and regulatory matters. He also contributes valuable strategic M&A acumen to the Board, supporting discussions on identifying potential growth opportunities and market expansion possibilities. His legal background as a former public company general counsel, combined with extensive public company board experience, contributes strong legal and governance expertise to the Board.
Skills and Qualifications
Consumer Products
Global Businesses
Life Sciences
Manufacturing and Supply
Marketing and Sales
Mergers and Acquisitions
Other Public Company Board Member
Public Company GC; Compliance; or Corporate Governance
Public Company CEO
Nearly 30 years of executive leadership experience in the pharmaceutical industry, having served as executive chairman, president and chief executive officer across multiple global pharmaceutical companies including Allergan plc (formerly Actavis plc) and Amneal Pharmaceuticals, Inc. (formerly Impax Laboratories Inc.), demonstrating proven ability to lead complex organizations through periods of significant growth and transformation.
Played a leading role in growing Allergan plc through, among other things, strategic M&A activity and served as Senior Vice President - Strategic Business Development, Chief Operating Officer and member of the Board of Directors at Barr Pharmaceuticals, Inc., bringing extensive deal experience and consistently identifying acquisition opportunities and market expansion possibilities to drive corporate growth.
Deep expertise in pharmaceutical manufacturing operations and R&D processes, having been responsible for global manufacturing operations at Barr Pharmaceuticals, and R&D priorities that uniquely qualifying him for service on the Quality & Innovation Committee.
Extensive public company board and governance expertise, currently serving on the Board of Directors of Myriad Genetics, Inc. and Keenova Therapeutics plc (formerly Mallinckrodt plc), with previous service on multiple pharmaceutical company boards, including Allergan plc (and its predecessor companies), Zimmer Biomet Holdings, Inc., Amneal Pharmaceuticals and TherapeuticsMD, Inc., and leveraging his legal background as former general counsel to provide valuable insights on corporate governance best practices and shareholder matters.
Career Highlights:
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) – a global specialty pharmaceutical company
- Executive Chairman (2018-2019)
Impax Laboratories, Inc. – a specialty pharmaceutical company
- President and Chief Executive Officer (2017-2018)
Allergan plc (formerly Actavis plc) (NYSE: AGN) – a global pharmaceutical company
- Executive Chairman of the Board of Directors (2014-2016)
Actavis (formerly Watson Pharmaceuticals) (NYSE: ACT) – a global pharmaceutical company
- Board Chairman, President and Chief Executive Officer (2013-2014)
- President, Chief Executive Officer and Board Member (2007-2013)
Barr Pharmaceuticals, Inc. – a global specialty and generic drug manufacturer
- President, Chief Operating Officer and Board Member (1999-2007)
- Senior Vice President - Strategic Business Development (1997-1999)
- General Counsel (1992-1999)
Education:
- Bachelor’s degree in General Studies from the University of Michigan
- Juris Doctor from The Catholic University of America